Longevity Supplements: What Actually Works

The longevity supplement market is growing fast. The gap between animal studies and human clinical evidence remains wide. These are the ingredients where meaningful human data actually exists.

NMN (nicotinamide mononucleotide) is a direct precursor to NAD+, a molecule central to cellular energy metabolism, DNA repair, and mitochondrial function. NAD+ levels decline with age, and this decline is associated with reduced cellular repair capacity and mitochondrial dysfunction. A clinical trial from Washington University found that NMN supplementation raised blood NAD+ levels and improved muscle insulin sensitivity in older adults. Long-term lifespan effects in humans have not been demonstrated, but the metabolic mechanisms are well-established.

Urolithin A is produced when gut bacteria convert ellagitannins, found in pomegranates and certain berries, into this bioactive compound. It activates mitophagy, the process by which cells clear damaged mitochondria, which is critical for maintaining cellular quality. A clinical study by Amazentis found that urolithin A supplementation improved muscle endurance in middle-aged and older adults. Because the ability to produce urolithin A from food varies significantly between individuals, direct supplementation can be meaningful for those who are poor converters.

Spermidine is a polyamine found naturally in wheat germ, aged cheese, and legumes. It induces autophagy, the broader cellular recycling process that clears damaged components and supports cell renewal. An Austrian clinical trial suggested potential benefits for cognitive function, and cardiovascular associations are under investigation.

All three have acceptable safety profiles, and larger long-term clinical trials are currently underway.

What This Means

No supplement can yet claim to extend human lifespan. But the science targeting cellular energy, mitochondrial health, and cellular cleanup processes is genuinely advancing. The gap between promising animal data and robust human trials is closing, slowly. Until it does, choose based on clinical evidence and transparent sourcing, not marketing language.